The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders. Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important ...
Other patterns of drug resistance There were an estimated 1.5 million incident cases (95% UI: 0.59–2.4 million) of isoniazid-resistant TB in 2024, including people with both rifampicin-susceptible and rifampicin-resistant TB. Globally in 2024, the estimated proportion of MDR/RR-TB cases with pre-XDR-TB (i.e. resistance to any fluoroquinolone for which testing was done) was 18% (95% UI: 15 ...
2.4 Drug-resistant TB: treatment enrolment, coverage and outcomes People with drug-resistant TB (DR-TB) need treatment with regimens that include second-line drugs, such as bedaquiline and fluoroquinolones (1).
MSN: Police make second drug arrest in March near NE Portland BottleDrop
RAPS: For Second Time Ever, FDA Awards Special Voucher Meant to Accelerate Drug Reviews
For Second Time Ever, FDA Awards Special Voucher Meant to Accelerate Drug Reviews Drugmaker United Therapeutics has become just the second company in US history to obtain a new type of voucher which ...
For Second Time Ever, FDA Awards Special Voucher Meant to Accelerate Drug Reviews
Scientific American: The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval
The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval
About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers. Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers ...